Zimbabwe’s Datlabs records strong growth and may revive its LVP plant
Bulawayo — Zimbabwean pharmaceutical company, Datlabs, which has recorded strong growth in a difficult operating environment, is considering reviving its large volume parenterals (LVP) plant to manufacture drips, currently imported at huge cost, mainly from SA. A subsidiary of JSE-listed Adcock Ingram, Datlabs manufactures pharmaceutical and personal-care products. Its critical-care division makes intravenous fluids. CEO Todd Moyo says Datlabs mothballed its multi-million dollar intravenous fluids factory in 2006 when there was a need to upgrade its equipment and after government, its major customer for drips, stopped buying due to financial constraints. The lack of sales was later compounded by the country receiving more than three year’s supply of drips from aid organisations to fight a serious cholera outbreak in 2009, which claimed more than 4,000 lives and infected more than 100,000 in Zimbabwe. "We are negotiating for the clearance of debt by government for LVPs and other phar...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.